Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Bachelot, Thomas ^a   Garcia Saenz, Jose A ^b   Verma, Sunil ^c   Gutierrez, Maya ^d   Pivot, Xavier ^e   Kozloff, Mark F ^f   Prady, Catherine ^g   Huang, Xin ^h   Khosravan, Reza ^h   Wang, Zhixiao ^i,k   Cesari, Rossano ^h   Tassell, Vanessa ^h,l   Kern, Kenneth A ^h   Blay, Jean Yves ^a,m   Lluch, Ana ^j  

^a CENTRE LÉON BÉRARD   (France)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d Medical Oncology   (France)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f Ingalls Memorial Hospital   (United States)

^g Centre intégré de cancérologie de la Montérégie CSSS Champlain Charles Lemoyne   (Canada)

^h PFIZER INC   (United States)

ⁱ Pfizer Ltd   (United States)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k EISAI INC   (United States)

^l Aragon Pharmaceuticals Inc   (United States)

^m UNIVERSITÉ LYON 1   (France)

more..

Author keywords

Advanced breast cancer; Sunitinib; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; N DEETHYLSUNITINIB; PLACEBO; SUNITINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INSOMNIA; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MOUTH DISCOMFORT; MOUTH DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SKIN DISEASE; STOMATITIS; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; METASTASIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CARDIOGENIC SHOCK; DISEASE SEVERITY; DRUG RESPONSE; DRUG WITHDRAWAL; HYPERTRANSAMINASEMIA; HYPONATREMIA; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PANCREATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PYRROLES; TREATMENT OUTCOME;

EID: 84899471382     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-166     Document Type: Article

References (39)

1. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3):719-726. 10.1200/JCO.20.3.719, 11821453.
2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17(9):2639-2648.
3. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004, 22(6):1063-1070. 10.1200/JCO.2004.06.557, 15020607.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792. 10.1056/NEJM200103153441101, 11248153.
5. Morrow PKH, Zambrana F, Esteva FJ. Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res 2009, 11(4):207-216. 10.1186/bcr2324, 2750101, 19664181.
6. Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Exp Op Pharmacother 2008, 9(15):2583-2601.
7. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models in human small cell lung cancer. Mol Cancer Ther 2003, 2(5):471-478.
8. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327-337.
9. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101(9):3597-3605. 10.1182/blood-2002-07-2307, 12531805.
10. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003, 20(8):757-766.
11. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006, 91(10):4070-4076. 10.1210/jc.2005-2845, 16849418.
12. Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 2011, 13(3):R66. 10.1186/bcr2903, 3218955, 21693010.
13. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26(11):1810-1816. 10.1200/JCO.2007.14.5375, 18347007.
14. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(25):4068-4075. 10.1200/JCO.2008.20.5476, 19652072.
15. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012, 118(5):1252-1259. 10.1002/cncr.26440, 21898376.
16. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009, 45(11):1959-1968. 10.1016/j.ejca.2009.02.011, 19282169.
17. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):501-513. Erratum in: N Engl J Med 2011, 364(11):1082, 10.1056/NEJMoa1003825, 21306237.
18. Finkenzeller G, Weindel K, Zimmermann W, Westin G, Marmé D. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis 2004, 7(1):59-68.
19. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004, 10(5):1706-1716. 10.1158/1078-0432.CCR-0951-3, 15014023.
20. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006, 66(4):2028-2037. 10.1158/0008-5472.CAN-04-4559, 16489002.
21. Pegram M, Chan D, Dichmann RA, Tan-Chiu E, Yeon C, Durna L, Lin LS, Slamon D. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 2006, 100:3039. abstract.
22. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23(10):2162-2171. 10.1200/JCO.2005.01.014, 15800309.
23. Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot X, Smirnova I, Moliterni A, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Provencher L, Moore N, Prot S, Semiglazov V. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/ metastatic breast cancer (LR/mBC). Cancer Res 2011, 71(24 Suppl):abstract S4-8.
24. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295. 10.1172/JCI200317929, 154450, 12727920.
25. Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006, 5(5):1280-1289. 10.1158/1535-7163.MCT-03-0156, 16731761.
26. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012, 30(9):921-929. 10.1200/JCO.2011.35.7376, 22331954.
27. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011, 11(2):82-92. 10.1016/j.clbc.2011.03.005, 21569994.
28. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121(1):121-131. 10.1007/s10549-010-0788-0, 2855860, 20339913.
29. Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH, Tassell V, Huang X, Paolini J, Kern KA, Romieu G. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013, 31(23):2870-2878. 10.1200/JCO.2012.43.3391, 23857972.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
31. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16(1):139-144.
32. Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012, 18(11):3170-9. 10.1158/1078-0432.CCR-11-3005, 22661587.
33. Yao VJ, Sennino B, Davis RB, Christensen J, Hu-Lowe D, Roberts G, McDonald DM. Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models. European Journal of Cancer Supplements 2006, 4(12):27-28.
34. Genentech, Inc Herceptin (trastuzumab) prescribing information. 2010, Available at: www/gene.com/gene/products/information/pdf/herceptin-prescribing.pdf, Genentech, Inc.
35. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20(5):1215-1221. 10.1200/JCO.20.5.1215, 11870163.
36. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370(9604):2011-2019. 10.1016/S0140-6736(07)61865-0, 2643085, 18083403.
37. Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S. Cardiovascular toxicity following suntinib therapy in metastatic renal cell carcinoma: a multicentre analysis. Ann Oncol 2009, 20(9):1535-1542. 10.1093/annonc/mdp025, 19474115.
38. 2(abstract 506P).
39. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011, 37(4):300-311. 10.1016/j.ctrv.2010.11.001, 21126826.